

European Transparency - Lessons Learned from the American Experience

Moderator:

Brian Sharkey, Porzio Life Sciences and Porzio Bromberg & Newman

Panelists:

Ryan Burger, *AstraZeneca*


Audrey DeGuarde, *Porzio Life Sciences*

Ami Patel, *Johnson & Johnson*



Compliance 2.0 – The Next Level
Seton Hall Law School
December 3, 2015

efpia*




Stichting
Transparantieregister
Zorg





United States



Europe




European Federation of Pharmaceutical
Industries and Associations

EFPIA HCP/HCO DISCLOSURE CODE

EFPIA CODE ON DISCLOSURE OF
TRANSFERS OF VALUE FROM
PHARMACEUTICAL COMPANIES TO
HEALTHCARE PROFESSIONALS AND
HEALTHCARE ORGANISATIONS

CONSOLIDATED VERSION 2014
Approved by the General Assembly of 6 June



1st Reports in 2016 to cover 2015 data

EFPIA Template

SCHEDULE 2 - TEMPLATE

Date of publication:

	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country Identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			TOTAL OPTIONAL	
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract				
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: Itemization should be available for the Individual Recipient or public authorities' consultation only, as appropriate)													
	Dr A					N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount			
	Dr B					N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount			
	etc.					N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount			
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						N/A	N/A	Aggregate HCPs	Aggregate HCPs	Aggregate HCPs	Aggregate HCPs		Optional
	Number of Recipients in aggregate disclosure - Art. 3.02						N/A	N/A	number	number	number	number		Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						N/A	N/A	%	%	%	%		N/A	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: Itemization should be available for the Individual Recipient or public authorities' consultation only, as appropriate)													
	HCO 1					Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount		Optional	
	HCO 2					Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount		Optional	
	etc.					Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount		Optional	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs		Optional
	Number of Recipients in aggregate disclosure - Art. 3.02						number	number	number	number	number	number		Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						%	%	%	%	%	%		N/A	
R & D	AGGREGATE DISCLOSURE													
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											TOTAL AMOUNT	OPTIONAL	

latest update: 11 December 2013 v1

- 
- A map of Europe is shown in the background. Blue dots are placed on the map to indicate specific regions of focus: one in the North Atlantic (Iceland), one in Scandinavia (Sweden), one in Central Europe (Germany), one in Western Europe (France), one in Southern Europe (Italy), and one in Eastern Europe (Russia).
- Consent
 - Methodology
 - Cross-Border
 - Language
 - Platform
 - R&D
 - Revocation
 - HCP
 - Management
 - Press
 - Laws
 - Rest of the World
 - Benefits